Literature DB >> 25124073

Pulsed-high-dose dexamethasone as a treatment for pure red cell aplasia following ABO-incompatible allogeneic stem cell transplantation.

X Yang1, M Levis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25124073      PMCID： PMC4695985          DOI： 10.1111/tme.12143

Source DB:  PubMed          Journal:  Transfus Med        ISSN： 0958-7578            Impact factor:   2.019


× No keyword cloud information.
  11 in total

1.  High-dose intravenous methylprednisolone for pure red cell aplasia.

Authors:  S Ozsoylu
Journal:  Am J Hematol       Date:  1990-07       Impact factor: 10.047

2.  Pure red-cell aplasia of long duration after major ABO-incompatible bone marrow transplantation.

Authors:  L Volin; T Ruutu
Journal:  Acta Haematol       Date:  1990       Impact factor: 2.195

3.  Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review.

Authors:  M H Yang; H C Hsu
Journal:  Ann Hematol       Date:  2001-05       Impact factor: 3.673

4.  Response to high-dose dexamethasone for acquired pure red cell aplasia following ABO-mismatched allogeneic stem cell transplantation.

Authors:  U R Deotare; A Vishwabandya; V Mathews; B George; A Srivastava; M Chandy
Journal:  Bone Marrow Transplant       Date:  2006-05-08       Impact factor: 5.483

5.  High-dose glucocorticoid treatment of resistant myeloma.

Authors:  R Alexanian; B Barlogie; D Dixon
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

6.  Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation.

Authors:  J H Lee; K H Lee; S Kim; J S Lee; S H Kim; S W Kwon; W K Kim
Journal:  Bone Marrow Transplant       Date:  2000-01       Impact factor: 5.483

Review 7.  Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.

Authors:  S D Rowley; M L Donato; P Bhattacharyya
Journal:  Bone Marrow Transplant       Date:  2011-09       Impact factor: 5.483

8.  Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation.

Authors:  F Khan; M A Linden; N D Zantek; G M Vercellotti
Journal:  Transfus Med       Date:  2014-05-09       Impact factor: 2.019

Review 9.  Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation.

Authors:  Mark H Yazer; Darrell J Triulzi
Journal:  Curr Opin Hematol       Date:  2007-11       Impact factor: 3.284

10.  Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility.

Authors:  J Mehta; R Powles; S Singhal; C Horton; M Hamblin; A Zomas; R Saso; J Treleaven
Journal:  Bone Marrow Transplant       Date:  1996-07       Impact factor: 5.483
View more
  2 in total

Review 1.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

2.  Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation.

Authors:  Yang Gao; Fei Gao; Jimin Shi; Huarui Fu; He Huang; Yanmin Zhao
Journal:  J Zhejiang Univ Sci B       Date:  2021-08-15       Impact factor: 3.066
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.